Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C21H41N5O7.5H2O4S |
| Molecular Weight | 1441.551 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 22 / 22 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O.CCN[C@@H]4C[C@H](N)[C@@H](O[C@H]5OC(CN)=CC[C@H]5N)[C@H](O)[C@H]4O[C@H]6OC[C@](C)(O)[C@H](NC)[C@H]6O
InChI
InChIKey=AGFWIZQEWFGATK-UNZHCMSXSA-N
InChI=1S/2C21H41N5O7.5H2O4S/c2*1-4-26-13-7-12(24)16(32-19-11(23)6-5-10(8-22)31-19)14(27)17(13)33-20-15(28)18(25-3)21(2,29)9-30-20;5*1-5(2,3)4/h2*5,11-20,25-29H,4,6-9,22-24H2,1-3H3;5*(H2,1,2,3,4)/t2*11-,12+,13-,14+,15-,16-,17+,18-,19-,20-,21+;;;;;/m11...../s1
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C21H41N5O7 |
| Molecular Weight | 475.5795 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00955Curator's Comment: Description was created based on several sources, including http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20N)/NETROMYCIN.html
Sources: http://www.drugbank.ca/drugs/DB00955
Curator's Comment: Description was created based on several sources, including http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20N)/NETROMYCIN.html
Netilmicin is a semisynthetic, water soluble antibiotic of the aminoglycoside group, produced by the fermentation of Micromonospora inyoensis, a species of actinomycete. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. It is active at low concentrations against a wide variety of pathogenic bacteria including Escherichia coli, bacteria of the Klebsiella-Enterobacter-Serratia group, Citrobacter sp., Proteus sp. (indole-positive and indole-negative), including Proteus mirabilis, P. morganii, P. rettgrei, P. vulgaris, Pseudomonas aeruginosa and Neisseria gonorrhoea. Netilmicin is also active in vitro against isolates of Hemophilus influenzae, Salmonella sp., Shigella sp. and against penicillinase and non-penicillinase-producing Staphylococcus including methicillin-resistant strains. Some strains of Providencia sp., Acinetobacter sp. and Aeromonas sp. are also sensitive to netilmicin. Many strains of the above organisms which are found to be resistant to other aminoglycosides, such as kanamycin, gentamicin, tobramycin and sisomicin, are susceptible to netilmicin in vitro. Occasionally, strains have been identified which are resistant to amikacin but susceptible to netilmicin. The combination of netilmicin and penicillin G has a synergistic bactericidal effect against most strains of Streptococcus faecalis (enterococcus). The combined effect of netilmicin and carbenicillin or ticarcillin is synergistic for many strains of Pseudomonas aeruginosa. In addition, many isolates of Serratia, which are resistant to multiple antibiotics, are inhibited by synergistic combinations of netilmicin with carbenicillin, azlocillin, mezlocillin, cefamandole, cefotaxime or moxalactam. Netilmicin "irreversibly" binds to specific 30S-subunit proteins and 16S rRNA. Specifically netilmicin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes, leaving the bacterium unable to synthesize proteins vital to its growth.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Ornithine decarboxylase (guinea pig) Sources: http://www.ncbi.nlm.nih.gov/pubmed/3377830 |
1.7 mM [Ki] | ||
Target ID: CHEMBL2280 Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=7473599 |
0.11565 mM [IC50] | ||
Target ID: 16S rRNA Sources: http://www.drugbank.ca/drugs/DB00955 |
|||
Target ID: HIV-1 replication Sources: http://www.ncbi.nlm.nih.gov/pubmed/21706033 |
23.1 µM [IC50] | ||
Target ID: CHEMBL1641336 Sources: http://www.drugbank.ca/drugs/DB00955 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | NETROMYCIN Approved UseIn the US, Netilmicin is a member of the drug class aminoglycosides and is used to treat Bacterial Infection and Urinary Tract Infection. Launch Date1983 |
|||
| Curative | Unknown Approved UseUnknown |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
76.9 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11450885 |
4.5 mg/kg single, intravenous dose: 4.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NETILMICIN serum | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11450885 |
4.5 mg/kg single, intravenous dose: 4.5 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
NETILMICIN serum | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
6 mg/kg 1 times / day steady, intravenous Studied dose Dose: 6 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 6 mg/kg, 1 times / day Sources: |
unhealthy, 26-42 weeks Health Status: unhealthy Age Group: 26-42 weeks Sex: M+F Sources: |
|
1.5 mg/kg 3 times / day steady, intravenous|intramuscular Studied dose Dose: 1.5 mg/kg, 3 times / day Route: intravenous|intramuscular Route: steady Dose: 1.5 mg/kg, 3 times / day Sources: |
unhealthy, 36.8 years (range: 14-79 years) Health Status: unhealthy Age Group: 36.8 years (range: 14-79 years) Sex: M+F Sources: |
Other AEs: Pain... |
4.5 mg/kg 1 times / day steady, intravenous|intramuscular Studied dose Dose: 4.5 mg/kg, 1 times / day Route: intravenous|intramuscular Route: steady Dose: 4.5 mg/kg, 1 times / day Sources: |
unhealthy, 40.3 years (range: 18-80 years) Health Status: unhealthy Age Group: 40.3 years (range: 18-80 years) Sex: M+F Sources: |
Other AEs: Pain... |
2.5 mg/kg 3 times / day steady, intramuscular Studied dose Dose: 2.5 mg/kg, 3 times / day Route: intramuscular Route: steady Dose: 2.5 mg/kg, 3 times / day Sources: |
unhealthy, old |
|
3.6 mg/kg 3 times / day steady, intramuscular Highest studied dose Dose: 3.6 mg/kg, 3 times / day Route: intramuscular Route: steady Dose: 3.6 mg/kg, 3 times / day Sources: |
unhealthy |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Pain | mild | 1.5 mg/kg 3 times / day steady, intravenous|intramuscular Studied dose Dose: 1.5 mg/kg, 3 times / day Route: intravenous|intramuscular Route: steady Dose: 1.5 mg/kg, 3 times / day Sources: |
unhealthy, 36.8 years (range: 14-79 years) Health Status: unhealthy Age Group: 36.8 years (range: 14-79 years) Sex: M+F Sources: |
| Pain | mild | 4.5 mg/kg 1 times / day steady, intravenous|intramuscular Studied dose Dose: 4.5 mg/kg, 1 times / day Route: intravenous|intramuscular Route: steady Dose: 4.5 mg/kg, 1 times / day Sources: |
unhealthy, 40.3 years (range: 18-80 years) Health Status: unhealthy Age Group: 40.3 years (range: 18-80 years) Sex: M+F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. | 2011-06-26 |
|
| In-vitro activity of seventeen antimicrobial compounds against seven species of mycobacteria. | 1988-12 |
|
| Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. | 1987-10 |
Patents
Sample Use Guides
Adult: 4-6 mg/kg once daily or in equally divided doses given every 8 or 12 hours. Life-threatening infections: Increase to up to 7.5 mg/kg daily every 8 hours. Treatment is usually given for 7-14 days. Child: Premature infants and neonates <1 week: 6 mg/kg daily in divided doses every 12 hours. Infants and neonates >1 week: 7.5-9 mg/kg daily in divided doses every 8 hours. Older children: 6-7.5 mg/kg daily in divided doses every 8 hours. Alternative regimen: Neonates <6 weeks: 4-6.5 mg/kg daily in divided doses every 12 hours. Older infants and children: 5.5-8 mg/kg daily in divided doses every 8 or 12 hours.
Route of Administration:
Other
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/879733
Curator's Comment: In Ca2+- and Mg2+-adjusted broth, the netilmicin MIC for gentamicin-susceptible P. aeruginosa was 9.6 ug/ml, and for gentamicin-resistant strains it was 23.1 ug/ml, an 18-fold increase.
MIC (Minimum inhibitory concentration) of netilmicin against P. aeruginosa in unadjusted broth was 0.73 ug/ml for gentamicin-susceptible strains and 1.35 ug/ml for gentamicin-resistant strains
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:45 GMT 2025
by
admin
on
Mon Mar 31 18:13:45 GMT 2025
|
| Record UNII |
S741ZJS97U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C2363
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL1572
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
260-147-3
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
203193
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | RxNorm | ||
|
1460500
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
56391-57-2
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
DBSALT001164
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
m7834
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | Merck Index | ||
|
S741ZJS97U
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
100000085716
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
SUB03415MIG
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
C66237
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
62115
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY | |||
|
DTXSID8045484
Created by
admin on Mon Mar 31 18:13:45 GMT 2025 , Edited by admin on Mon Mar 31 18:13:45 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |